Kopran added

Reasons for buying:

Buy PE was reasonable at 19.43 and above 10 years PE median of 11.22.

The 5-year earnings average is 25.2% and earnings are lackluster.

Return on equity is good at 28.34% but the 5-year average is 17.67%.

The market cap of the company is ₹1,285.05 Cr.

The debt of the company is ₹66.30 Cr with ₹7.98 Cr in cash.

Buy date: 28-Apr-2022

Qty: 38 Buy Price: ₹263 Buy EPS: 13.53 Buy PE: 19.43

***

Buy date: 12-May-2022

Qty: 42 Buy Price: ₹229.85 Buy EPS: 13.54 Buy PE: 16.98

***

Buy date: 06-July-2022

Qty: 50 Buy Price: ₹196.7 Buy EPS: 14.24 Buy PE: 13.81

***

Buy date: 16-Aug-2022

Qty: 54 Buy Price: ₹184 Buy EPS: 13.86 Buy PE: 13.27

***

Buy date: 03-Oct-2022

Qty: 63 Buy Price: ₹157 Buy EPS: 13.86 Buy PE: 11.32

I will stop buying when EPS drops to 13.15 since I have purchased at 20 PE.

Kopran Ltd. is a holding company, which engages in the manufacturing of pharmaceuticals and related products. It operates through the following business units: Formulations, and Active Pharmaceutical Ingredients. The firm's products include Amyn, Lokit, and Ciproquin. The company was founded on April 26, 1958, and is headquartered in Mumbai, India.